MEMBER'S LOGINX
| Login Failure | ||||||||
|
||||||||
| Sign Up | Forgot Password? | ||||||||
- Home
- Research It
- Compare Company
- Indian - indian pharma
- CIPLA - SUN PHARMA
CIPLA vs SUN PHARMA - Comparison Results
CIPLA Change
Cipla is one of the largest pharma companies in the domestic market and has presence in formulations and bulk drugs manufacturing. All the bulk drug manufacturing facilities of the company have been approved by various authorities including the US FD... More
SUN PHARMA 
Sun Pharma holds 3.7% share of the domestic pharma market (as per the latest ORG IMS MAT data) and has a strong presence in the lifestyle therapeutic segments. The company started focusing on the exports market in FY02, when it increased its stake to... More
Current Valuations
| CIPLA | SUN PHARMA | CIPLA/ SUN PHARMA |
|||
|---|---|---|---|---|---|
| P/E (TTM) | x | 23.3 | 27.0 | 86.3% | View Chart |
| P/BV | x | 2.4 | 2.3 | 102.0% | View Chart |
| Dividend Yield | % | 0.7 | 0.7 | 98.7% |
Financials
 CIPLA  SUN PHARMA |
| EQUITY SHARE DATA | |||||
|---|---|---|---|---|---|
| CIPLA Mar-19 |
SUN PHARMA Mar-19 |
CIPLA/ SUN PHARMA |
5-Yr Chart Click to enlarge
|
||
| High | Rs | 678 | 679 | 99.9% | |
| Low | Rs | 484 | 375 | 128.9% | |
| Sales per share (Unadj.) | Rs | 198.2 | 121.1 | 163.6% | |
| Earnings per share (Unadj.) | Rs | 18.5 | 13.4 | 138.5% | |
| Cash flow per share (Unadj.) | Rs | 35.0 | 20.7 | 169.1% | |
| Dividends per share (Unadj.) | Rs | 3.00 | 2.75 | 109.1% | |
| Dividend yield (eoy) | % | 0.5 | 0.5 | 99.0% | |
| Book value per share (Unadj.) | Rs | 186.3 | 172.6 | 108.0% | |
| Shares outstanding (eoy) | m | 805.70 | 2,399.26 | 33.6% | |
| Bonus/Rights/Conversions | ESOP | - | - | ||
| Price / Sales ratio | x | 2.9 | 4.4 | 67.4% | |
| Avg P/E ratio | x | 31.4 | 39.4 | 79.6% | |
| P/CF ratio (eoy) | x | 16.6 | 25.5 | 65.2% | |
| Price / Book Value ratio | x | 3.1 | 3.1 | 102.1% | |
| Dividend payout | % | 16.2 | 20.6 | 78.8% | |
| Avg Mkt Cap | Rs m | 468,031 | 1,264,650 | 37.0% | |
| No. of employees | `000 | 22.6 | 17.5 | 129.4% | |
| Total wages/salary | Rs m | 28,565 | 59,671 | 47.9% | |
| Avg. sales/employee | Rs Th | 7,053.1 | 16,608.1 | 42.5% | |
| Avg. wages/employee | Rs Th | 1,261.5 | 3,409.6 | 37.0% | |
| Avg. net profit/employee | Rs Th | 659.1 | 1,833.8 | 35.9% | |
| INCOME DATA | |||||
|---|---|---|---|---|---|
| Net Sales | Rs m | 159,710 | 290,659 | 54.9% | |
| Other income | Rs m | 4,766 | 10,255 | 46.5% | |
| Total revenues | Rs m | 164,475 | 300,914 | 54.7% | |
| Gross profit | Rs m | 30,973 | 63,076 | 49.1% | |
| Depreciation | Rs m | 13,263 | 17,533 | 75.6% | |
| Interest | Rs m | 1,684 | 5,553 | 30.3% | |
| Profit before tax | Rs m | 20,791 | 50,246 | 41.4% | |
| Minority Interest | Rs m | -172 | 0 | - | |
| Prior Period Items | Rs m | 0 | 0 | - | |
| Extraordinary Inc (Exp) | Rs m | 0 | -12,144 | 0.0% | |
| Tax | Rs m | 5,695 | 6,009 | 94.8% | |
| Profit after tax | Rs m | 14,924 | 32,093 | 46.5% | |
| Gross profit margin | % | 19.4 | 21.7 | 89.4% | |
| Effective tax rate | % | 27.4 | 12.0 | 229.1% | |
| Net profit margin | % | 9.3 | 11.0 | 84.6% | |
| BALANCE SHEET DATA | |||||
|---|---|---|---|---|---|
| Current assets | Rs m | 124,266 | 310,692 | 40.0% | |
| Current liabilities | Rs m | 37,715 | 173,396 | 21.8% | |
| Net working cap to sales | % | 54.2 | 47.2 | 114.7% | |
| Current ratio | x | 3.3 | 1.8 | 183.9% | |
| Inventory Days | Days | 91 | 99 | 91.5% | |
| Debtors Days | Days | 95 | 112 | 85.0% | |
| Net fixed assets | Rs m | 105,190 | 232,477 | 45.2% | |
| Share capital | Rs m | 1,611 | 2,399 | 67.2% | |
| "Free" reserves | Rs m | 148,511 | 411,691 | 36.1% | |
| Net worth | Rs m | 150,123 | 414,091 | 36.3% | |
| Long term debt | Rs m | 38,301 | 15,226 | 251.5% | |
| Total assets | Rs m | 239,633 | 646,938 | 37.0% | |
| Interest coverage | x | 13.3 | 10.0 | 132.8% | |
| Debt to equity ratio | x | 0.3 | 0 | 693.9% | |
| Sales to assets ratio | x | 0.7 | 0.4 | 148.3% | |
| Return on assets | % | 6.9 | 5.8 | 119.1% | |
| Return on equity | % | 9.9 | 7.8 | 128.3% | |
| Return on capital | % | 11.8 | 10.2 | 116.4% | |
| Exports to sales | % | 34.7 | 0 | - | |
| Imports to sales | % | 0 | 0 | - | |
| Exports (fob) | Rs m | 55,419 | NA | - | |
| Imports (cif) | Rs m | NA | NA | - | |
| Fx inflow | Rs m | 57,410 | 66,025 | 87.0% | |
| Fx outflow | Rs m | 19,041 | 38,610 | 49.3% | |
| Net fx | Rs m | 38,368 | 27,415 | 140.0% | |
| CASH FLOW | |||||
|---|---|---|---|---|---|
| From Operations | Rs m | 16,911 | 21,965 | 77.0% | |
| From Investments | Rs m | -16,687 | -6,813 | 244.9% | |
| From Financial Activity | Rs m | -3,487 | -27,305 | 12.8% | |
| Net Cashflow | Rs m | -3,451 | -8,442 | 40.9% | |
Share Holding
| Indian Promoters | % | 16.0 | 63.7 | 25.1% | |
| Foreign collaborators | % | 20.8 | 0.0 | - | |
| Indian inst/Mut Fund | % | 12.2 | 5.1 | 237.8% | |
| FIIs | % | 23.7 | 23.0 | 103.0% | |
| ADR/GDR | % | 1.1 | 0.0 | - | |
| Free float | % | 26.2 | 8.3 | 315.7% | |
| Shareholders | 161,166 | 133,026 | 121.2% | ||
| Pledged promoter(s) holding | % | 0.0 | 0.5 | - |
Compare CIPLA With: STRIDES PHARMA SCIENCE AJANTA PHARMA UNICHEM LAB DR. DATSONS LABS ELDER PHARMA
Compare CIPLA With: MYLAN (US) ACTAVIS (US) ADCOCK INGRAM (S. Africa) TEVA PHARMA (Israel)
|
| |
Today's Market
Indian Stock Markets Remain in Green This Week: Is the Rebound Here?(Podcast)
After a long period of underperformance, stock markets traded in green territory throughout the week. So, is this is a trend reversal and is the bottom forming in the market?
Related Views on News
CIPLA 2018-19 Annual Report Analysis (Annual Result Update)
Sep 9, 2019 | Updated on Sep 9, 2019Here's an analysis of the annual report of CIPLA for 2018-19. It includes a full income statement, balance sheet and cash flow analysis of CIPLA. Also includes updates on the valuation of CIPLA.
SUN PHARMA Announces Quarterly Results (1QFY20); Net Profit Up 35.3% (Quarterly Result Update)
Aug 14, 2019 | Updated on Aug 14, 2019For the quarter ended June 2019, SUN PHARMA has posted a net profit of Rs 15 bn (up 35.3% YoY). Sales on the other hand came in at Rs 84 bn (up 15.9% YoY). Read on for a complete analysis of SUN PHARMA's quarterly results.
CIPLA Announces Quarterly Results (1QFY20); Net Profit Up 5.6% (Quarterly Result Update)
Aug 13, 2019 | Updated on Aug 13, 2019For the quarter ended June 2019, CIPLA has posted a net profit of Rs 5 bn (up 5.6% YoY). Sales on the other hand came in at Rs 40 bn (up 1.3% YoY). Read on for a complete analysis of CIPLA's quarterly results.
SUN PHARMA 2018-19 Annual Report Analysis (Annual Result Update)
Aug 6, 2019 | Updated on Aug 6, 2019Here's an analysis of the annual report of SUN PHARMA for 2018-19. It includes a full income statement, balance sheet and cash flow analysis of SUN PHARMA. Also includes updates on the valuation of SUN PHARMA.
SUN PHARMA Announces Quarterly Results (4QFY19); Net Profit Down 53.4% (Quarterly Result Update)
May 30, 2019 | Updated on May 30, 2019For the quarter ended March 2019, SUN PHARMA has posted a net profit of Rs 7 bn (down 53.4% YoY). Sales on the other hand came in at Rs 72 bn (up 2.7% YoY). Read on for a complete analysis of SUN PHARMA's quarterly results.
More Views on NewsMost Popular
My 3 Best Small-cap Stocks to Get Rich in this Market Rebound(Profit Hunter)
Oct 14, 2019This is once in a decade opportunity to make a killing from smallcap rebound.
Finally, Is the Share Price of Yes Bank Ready for a Rebound?(The 5 Minute Wrapup)
Oct 7, 2019Here's what every individual investor must know about Yes Bank...
Two Stocks to Buy in the Great Indian Festival(Profit Hunter)
Oct 11, 2019Discounts are not just limited to E-tailers. You can buy stocks at 50% off too. Here are two stocks to buy now.
The One Stock I Like in this Market(The 5 Minute Wrapup)
Oct 10, 2019There are rare periods in markets when you get good quality stocks at attractive valuations. Is this one such period?
5 Smart Money Stocks to Profit from the Market Rebound(The 5 Minute Wrapup)
Oct 11, 2019Now is the time to put money in these 5 stocks to take advantage of the recovery in the economy and the markets.
MoreCIPLA SHARE PRICE
Oct 18, 2019 (Close)
TRACK CIPLA
- Track your investment in CIPLA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
- Add To MyStocks
MORE ON CIPLA
CIPLA 8-QTR ANALYSIS
COMPARE CIPLA WITH
OTHER USEFUL LINKS
MARKET STATS
ABOUT EQUITYMASTER
Since 1996, Equitymaster has been the source for honest and credible opinions on investing in India. With solid research and in-depth analysis Equitymaster is dedicated towards making its readers- smarter, more confident and richer every day. Here's why hundreds of thousands of readers spread across more than 70 countries Trust Equitymaster.
FREE NEWSLETTERS
PREMIUM PRODUCTS
QUICK LINKS
APPS
FOLLOW
Copyright © Equitymaster Agora Research Private Limited.
Whitelist | Refer | Terms | Privacy | Contact | About | Sitemap
Equitymaster Agora Research Private Limited (Research Analyst) 103, Regent Chambers, Above Status Restaurant, Nariman Point, Mumbai - 400 021. India.
Telephone: +91-22-61434055. Fax: +91-22-22028550. Email: info@equitymaster.com. Website: www.equitymaster.com. CIN:U74999MH2007PTC175407
All rights reserved. Any act of copying, reproducing or distributing this newsletter whether wholly or in part, for any purpose without the permission of Equitymaster is strictly prohibited and shall be deemed to be copyright infringement.
LEGAL DISCLAIMER: Equitymaster Agora Research Private Limited (Research Analyst) bearing Registration No. INH000000537 (hereinafter referred as 'Equitymaster') is an independent equity research Company. Equitymaster is not an Investment Adviser. Information herein should be regarded as a resource only and should be used at one's own risk. This is not an offer to sell or solicitation to buy any securities and Equitymaster will not be liable for any losses incurred or investment(s) made or decisions taken/or not taken based on the information provided herein. Information contained herein does not constitute investment advice or a personal recommendation or take into account the particular investment objectives, financial situations, or needs of individual subscribers. Before acting on any recommendation, subscribers should consider whether it is suitable for their particular circumstances and, if necessary, seek an independent professional advice. This is not directed for access or use by anyone in a country, especially, USA, Canada or the European Union countries, where such use or access is unlawful or which may subject Equitymaster or its affiliates to any registration or licensing requirement. All content and information is provided on an 'As Is' basis by Equitymaster. Information herein is believed to be reliable but Equitymaster does not warrant its completeness or accuracy and expressly disclaims all warranties and conditions of any kind, whether express or implied. Equitymaster may hold shares in the company/ies discussed herein. As a condition to accessing Equitymaster content and website, you agree to our Terms and Conditions of Use, available here. The performance data quoted represents past performance and does not guarantee future results.
SEBI (Research Analysts) Regulations 2014, Registration No. INH000000537.